Brodalumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Interleukin 17 receptor A |
| Clinical data | |
| ATC code | L04AC12 (WHO) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
1174395-19-7  |
| ChemSpider | none |
| KEGG |
D10061 |
| Chemical and physical data | |
| Formula | C6372H9840N1712O1988S52 |
| Molar mass | 144.06 kg/mol |
 (what is this?) (verify) | |
Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases.[1]
As of January 2016 it is awaiting an FDA decision on its use for the treatment of moderate to severe psoriasis.[2]
History
Brodalumab was developed by Amgen, Inc.
In 2013 it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.[3][4]
In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.[5]
However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior".[6] AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab.
In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab.[7] In July of 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.[8]
In January 2016, a Biologics License Application (BLA) was submitted to the US FDA. A response is due by November 2016.[2]
Mechanism of action
Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. (This mechanism is similar to that of another anti-psoriasis antibody, ixekizumab, which however binds to IL-17 itself.)
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association.
- 1 2 FDA accepts AstraZeneca's brodalumab BLA for plaque psoriasis, PDUFA date November 16Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis. Jan 2016
- ↑ Clinical trial number NCT01708590 for "Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT01708629 for "Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)" at ClinicalTrials.gov
- ↑ http://www.genengnews.com/gen-news-highlights/brodalumab-s-no-turkey-in-phase-iii-amgen-and-astrazeneca/81250645/
- ↑ "Amgen to terminate participation in co-development and commercialization of brodaluma". Amgen.
- ↑ http://www.astrazeneca.com/Media/Press-releases/Article/20150901--astrazeneca-and-valeant-pharmaceuticals-partnership
- ↑ https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-enters-licensing-agreements-with-leo-pharma-in-skin-diseases-01072016.html